Plain-English translation of NCT04113486 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a protein called nicotinamide metabolism-related protein (NMAP) found in the blood to see if it could be a useful marker for diagnosing kidney cancer. They want to measure NMAP levels in people with kidney cancer and compare them to people without cancer to determine if this protein could help doctors detect kidney cancer more accurately.
Currently, kidney cancer is often detected late because there are no reliable early warning signs. Finding a simple blood test that can identify kidney cancer would help doctors catch the disease sooner, when treatment is more effective.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will have one blood sample taken, which will be tested to measure the NMAP protein level. You may already be scheduled for kidney or liver surgery as part of your medical care — this study simply involves giving a blood sample before or around the time of that surgery. The study involves no additional medications or procedures beyond the blood draw.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Enrollment target
~400 participants
Started
October 2019
Primary completion
January 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Min NA Shi, MD
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.